151 related articles for article (PubMed ID: 18089714)
1. TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.
Derosier LC; Vickers SM; Zinn KR; Huang Z; Wang W; Grizzle WE; Sellers J; Stockard CR; Zhou T; Oliver PG; Arnoletti P; Lobuglio AF; Buchsbaum DJ
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3198-207. PubMed ID: 18089714
[TBL] [Abstract][Full Text] [Related]
2. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
[TBL] [Abstract][Full Text] [Related]
3. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.
DeRosier LC; Buchsbaum DJ; Oliver PG; Huang ZQ; Sellers JC; Grizzle WE; Wang W; Zhou T; Zinn KR; Long JW; Vickers SM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5535s-5543s. PubMed ID: 17875786
[TBL] [Abstract][Full Text] [Related]
4. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.
Kim H; Zhai G; Samuel SL; Rigell CJ; Umphrey HR; Rana S; Stockard CR; Fineberg NS; Zinn KR
Mol Cancer Ther; 2012 Feb; 11(2):405-15. PubMed ID: 22203731
[TBL] [Abstract][Full Text] [Related]
5. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
[TBL] [Abstract][Full Text] [Related]
7. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
[TBL] [Abstract][Full Text] [Related]
8. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging.
Kim H; Morgan DE; Buchsbaum DJ; Zeng H; Grizzle WE; Warram JM; Stockard CR; McNally LR; Long JW; Sellers JC; Forero A; Zinn KR
Cancer Res; 2008 Oct; 68(20):8369-76. PubMed ID: 18922909
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
[TBL] [Abstract][Full Text] [Related]
10. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ
Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
Kimura K; Sawada T; Komatsu M; Inoue M; Muguruma K; Nishihara T; Yamashita Y; Yamada N; Ohira M; Hirakawa K
Clin Cancer Res; 2006 Aug; 12(16):4925-32. PubMed ID: 16914581
[TBL] [Abstract][Full Text] [Related]
12. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.
Yuan K; Sun Y; Zhou T; McDonald J; Chen Y
Clin Cancer Res; 2013 Sep; 19(17):4750-9. PubMed ID: 23833311
[TBL] [Abstract][Full Text] [Related]
13. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
14. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model.
Kawaguchi K; Igarashi K; Miyake K; Lwin TM; Miyake M; Kiyuna T; Hwang HK; Murakami T; Delong JC; Singh SR; Clary B; Bouvet M; Unno M; Hoffman RM
Tissue Cell; 2018 Jun; 52():124-128. PubMed ID: 29857821
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Bianco C; Giovannetti E; Ciardiello F; Mey V; Nannizzi S; Tortora G; Troiani T; Pasqualetti F; Eckhardt G; de Liguoro M; Ricciardi S; Del Tacca M; Raben D; Cionini L; Danesi R
Clin Cancer Res; 2006 Dec; 12(23):7099-107. PubMed ID: 17145834
[TBL] [Abstract][Full Text] [Related]
16. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.
Buchsbaum DJ; Bonner JA; Grizzle WE; Stackhouse MA; Carpenter M; Hicklin DJ; Bohlen P; Raisch KP
Int J Radiat Oncol Biol Phys; 2002 Nov; 54(4):1180-93. PubMed ID: 12419447
[TBL] [Abstract][Full Text] [Related]
17. Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity.
Kaliberov SA; Chiz S; Kaliberova LN; Krendelchtchikova V; Della Manna D; Zhou T; Buchsbaum DJ
Cancer Gene Ther; 2006 Feb; 13(2):203-14. PubMed ID: 16082379
[TBL] [Abstract][Full Text] [Related]
18. Effect of anti-DR5 and chemotherapy on basal-like breast cancer.
Oliver PG; LoBuglio AF; Zhou T; Forero A; Kim H; Zinn KR; Zhai G; Li Y; Lee CH; Buchsbaum DJ
Breast Cancer Res Treat; 2012 Jun; 133(2):417-26. PubMed ID: 21901385
[TBL] [Abstract][Full Text] [Related]
19. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
20. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Banerjee S; Zhang Y; Ali S; Bhuiyan M; Wang Z; Chiao PJ; Philip PA; Abbruzzese J; Sarkar FH
Cancer Res; 2005 Oct; 65(19):9064-72. PubMed ID: 16204081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]